VLA-4 retargeted adenovirus type 5 as vector for acute myeloid leukemia (CROSBI ID 573459)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa
Podaci o odgovornosti
Majhen, Dragomira ; Jelušić, Tihana ; Gabrilovac, Jelka ; Ambriović-Ristov, Andreja
engleski
VLA-4 retargeted adenovirus type 5 as vector for acute myeloid leukemia
Acute myeloid leukemia (AML) is a cancer of the myeloid line of white blood cells, characterized by the rapid proliferation of abnormal cells which accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. The basic therapeutic approach to patients with AML aged 18-60 years has changed little over the last 3 decades and classically involves chemotherapy treatment which is very invasive and elderly patient poorly tolerate its toxicity. Since less than 40% of AML patients under age of 60 can be cured, and in older adults, accounting for the majority of AML patients, long-term disease-free survival rate is rare with limited available treatment options, there is urgent need for the development of novel targeted therapies for AML. Gene therapy, with emphasis on receptor targeted gene delivery, might be a future option in treating AML.
adenovirus; VLA-4; retargeting
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
2009.
objavljeno
Podaci o matičnoj publikaciji
Targeting and Imaging of tumor microenvironment. Book of Abstracts.
Podaci o skupu
Targeting and Imaging of tumor microenvironment
predavanje
23.09.2009-26.09.2009
Ile Berder, Francuska